New cancer pill tested in early trial, but study stopped early

NCT ID NCT05605119

First seen Apr 18, 2026 · Last updated Apr 23, 2026 · Updated 1 time

Summary

This early-phase study tested an experimental oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had returned after prior treatment. The main goals were to check safety, find the right dose, and see how the drug moves through the body. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • ALL India Institute of medical Scieneces

    New Delhi, New Delhi, 110029, India

  • All India Institute of Medical Sciences

    Bhubaneswar, Odisha, 751019, India

  • HCG City Cancer Center

    Vijayawada, Andhra Pradesh, 520002, India

  • IMS&SUM Hospital

    Bhubaneswar, Bhubaneswar, 751003, India

  • Kailash Cancer Hospital and Research Centre

    Vadodara, Gujarat, 391760, India

  • Krupamayi Hospital

    Aurangabad, Maharashtra, 431001, India

  • Moraya Multi-Speciality Hospital

    Pune, Maharasthra, 411033, India

  • Omega Hospitals

    Visakhapatnam, Andhra Pradesh, 530040, India

  • Sparsh Hospital and Critical Care

    Bhubaneswar, Odisha, 751007, India

Conditions

Explore the condition pages connected to this study.